{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:19:54Z","timestamp":1793413194108,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40123-025-01093-3","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:46:22Z","timestamp":1738698382000},"page":"489-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["To Treat or Not to Treat? Resolving the Question of Subretinal and Intraretinal Fluid in Age-Related Macular Degeneration: A Narrative Review"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-0072","authenticated-orcid":false,"given":"Alexander J. E.","family":"Foss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"de Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Empeslidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-017-0023-4","volume":"1","author":"M Prem Senthil","year":"2017","unstructured":"Prem Senthil M, Khadka J, Gilhotra JS, Simon S, Pesudovs K. Exploring the quality of life issues in people with retinal diseases: a qualitative study. J Patient Rep Outcomes. 2017;1:15. https:\/\/doi.org\/10.1186\/s41687-017-0023-4.","journal-title":"J Patient Rep Outcomes"},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1007\/s12325-021-01672-3","volume":"38","author":"N Lopes","year":"2021","unstructured":"Lopes N, Dias LLDS, \u00c1vila M, et al. Humanistic and economic burden of blindness associated with retinal disorders in a Brazilian sample: a cross-sectional study. Adv Ther. 2021;38:4215\u201330. https:\/\/doi.org\/10.1007\/s12325-021-01672-3.","journal-title":"Adv Ther"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/pharmaceutics14050904","volume":"14","author":"A Ben-Arzi","year":"2022","unstructured":"Ben-Arzi A, Ehrlich R, Neumann R. Retinal diseases: the next frontier in pharmacodelivery. Pharmaceutics. 2022;14:904. https:\/\/doi.org\/10.3390\/pharmaceutics14050904.","journal-title":"Pharmaceutics"},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/s2214-109x(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221\u201334. https:\/\/doi.org\/10.1016\/s2214-109x(17)30393-5.","journal-title":"Lancet Glob Health"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1038\/s41467-019-11262-1","volume":"10","author":"JT Handa","year":"2019","unstructured":"Handa JT, Bowes Rickman C, Dick AD, et al. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019;10:3347. https:\/\/doi.org\/10.1038\/s41467-019-11262-1.","journal-title":"Nat Commun"},{"key":"1093_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29583","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14: e29583. https:\/\/doi.org\/10.7759\/cureus.29583.","journal-title":"Cureus"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/biomedicines12071479","volume":"12","author":"Bhumika","year":"2024","unstructured":"Bhumika, Bora NS, Bora PS. Genetic insights into age-related macular degeneration. Biomedicines. 2024;12:1479. https:\/\/doi.org\/10.3390\/biomedicines12071479.","journal-title":"Biomedicines."},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/s41433-024-03308-6","volume":"38","author":"BG Armendariz","year":"2024","unstructured":"Armendariz BG, Chakravarthy U. Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era. Eye (Lond). 2024;38:3243\u201351. https:\/\/doi.org\/10.1038\/s41433-024-03308-6.","journal-title":"Eye (Lond)"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2021.09.033","volume":"236","author":"A Mehta","year":"2022","unstructured":"Mehta A, Steel DH, Muldrew A, et al. Associations and outcomes of patients with submacular hemorrhage secondary to age-related macular degeneration in the IVAN trial. Am J Ophthalmol. 2022;236:89\u201398. https:\/\/doi.org\/10.1016\/j.ajo.2021.09.033.","journal-title":"Am J Ophthalmol"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004.","journal-title":"Ophthalmology"},{"key":"1093_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001214","volume":"8","author":"J Park","year":"2023","unstructured":"Park J, Felfeli T, Kherani IZ, Altomare F, Chow DR, Wong DT. Prevalence and clinical implications of subretinal fluid in retinal diseases: a real-world cohort study. BMJ Open Ophthalmol. 2023;8: e001214. https:\/\/doi.org\/10.1136\/bmjophth-2022-001214.","journal-title":"BMJ Open Ophthalmol"},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.3390\/cells11213453","volume":"11","author":"H Heloter\u00e4","year":"2022","unstructured":"Heloter\u00e4 H, Kaarniranta K. A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration. Cells. 2022;11:3453. https:\/\/doi.org\/10.3390\/cells11213453.","journal-title":"Cells"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3389\/fphar.2019.01363","volume":"10","author":"NJY Yeo","year":"2019","unstructured":"Yeo NJY, Chan EJJ, Cheung C. Choroidal neovascularization: mechanisms of endothelial dysfunction. Front Pharmacol. 2019;10:1363. https:\/\/doi.org\/10.3389\/fphar.2019.01363.","journal-title":"Front Pharmacol"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/cer-2018-0058","volume":"7","author":"DH Jaffe","year":"2018","unstructured":"Jaffe DH, Chan W, Bezlyak V, Skelly A. The economic and humanistic burden of patients in receipt of current available therapies for nAMD. J Comp Eff Res. 2018;7:1125\u201332. https:\/\/doi.org\/10.2217\/cer-2018-0058.","journal-title":"J Comp Eff Res"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","volume":"16","author":"A Hang","year":"2023","unstructured":"Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals (Basel). 2023;16:1140. https:\/\/doi.org\/10.3390\/ph16081140.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","journal-title":"Ophthalmology"},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1038\/s41598-023-32398-7","volume":"13","author":"S Moon","year":"2023","unstructured":"Moon S, Lee Y, Hwang J, et al. Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network. Sci Rep. 2023;13:5639. https:\/\/doi.org\/10.1038\/s41598-023-32398-7.","journal-title":"Sci Rep"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018.","journal-title":"Ophthalmology"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023;37:6\u201316. https:\/\/doi.org\/10.1038\/s41433-022-02020-7.","journal-title":"Eye (Lond)"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702.","journal-title":"Br J Ophthalmol"},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/opth.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391. https:\/\/doi.org\/10.2147\/opth.S185052.","journal-title":"Clin Ophthalmol"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787\u201394. https:\/\/doi.org\/10.1038\/eye.2013.107.","journal-title":"Eye (Lond)"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","volume":"13","author":"P Ma","year":"2022","unstructured":"Ma P, Pan X, Liu R, et al. Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2022;13:1017889. https:\/\/doi.org\/10.3389\/fphar.2022.1017889.","journal-title":"Front Pharmacol"},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41433-022-02221-0","volume":"37","author":"V Chaudhary","year":"2023","unstructured":"Chaudhary V. Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next? Eye (Lond). 2023;37:581\u20133. https:\/\/doi.org\/10.1038\/s41433-022-02221-0.","journal-title":"Eye (Lond)"},{"key":"1093_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101113","volume":"92","author":"R Sacconi","year":"2023","unstructured":"Sacconi R, Fragiotta S, Sarraf D, et al. Towards a better understanding of non-exudative choroidal and macular neovascularization. Prog Retin Eye Res. 2023;92: 101113. https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101113.","journal-title":"Prog Retin Eye Res"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"14166","DOI":"10.1038\/s41598-022-18158-z","volume":"12","author":"JH Kim","year":"2022","unstructured":"Kim JH, Sagong M, Woo SJ, et al. A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea. Sci Rep. 2022;12:14166. https:\/\/doi.org\/10.1038\/s41598-022-18158-z.","journal-title":"Sci Rep"},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"251584142210833","DOI":"10.1177\/25158414221083363","volume":"14","author":"GS Reiter","year":"2022","unstructured":"Reiter GS, Schmidt-Erfurth U. Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy. Ther Adv Ophthalmol. 2022;14:25158414221083363. https:\/\/doi.org\/10.1177\/25158414221083363.","journal-title":"Ther Adv Ophthalmol"},{"key":"1093_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/tvst.12.11.13","volume":"12","author":"A Berlin","year":"2023","unstructured":"Berlin A, Messinger JD, Balaratnasingam C, et al. Imaging histology correlations of intraretinal fluid in neovascular age-related macular degeneration. Transl Vis Sci Technol. 2023;12:13. https:\/\/doi.org\/10.1167\/tvst.12.11.13.","journal-title":"Transl Vis Sci Technol"},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41433-022-02360-4","volume":"37","author":"RLW Hanson","year":"2023","unstructured":"Hanson RLW, Airody A, Sivaprasad S, Gale RP. Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. Eye (Lond). 2023;37:2438\u201353. https:\/\/doi.org\/10.1038\/s41433-022-02360-4.","journal-title":"Eye (Lond)"},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s00417-022-05716-4","volume":"260","author":"S Sadda","year":"2022","unstructured":"Sadda S, Holekamp NM, Sarraf D, et al. Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis. Graefes Arch Clin Exp Ophthalmol. 2022;260:3781\u20139. https:\/\/doi.org\/10.1007\/s00417-022-05716-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"251584142110228","DOI":"10.1177\/25158414211022874","volume":"13","author":"D Yildiz","year":"2021","unstructured":"Yildiz D, Cakir A, Erden B, Bolukbasi S, Erden\u00f6z S, Elcioglu MN. Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept. Ther Adv Ophthalmol. 2021;13:25158414211022874. https:\/\/doi.org\/10.1177\/25158414211022874.","journal-title":"Ther Adv Ophthalmol"},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/bjophthalmol-2020-317326","volume":"105","author":"A Hilely","year":"2021","unstructured":"Hilely A, Au A, Freund KB, et al. Non-neovascular age-related macular degeneration with subretinal fluid. Br J Ophthalmol. 2021;105:1415\u201320. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317326.","journal-title":"Br J Ophthalmol"},{"key":"1093_CR35","first-page":"238","volume":"50","author":"B Madjarov","year":"2009","unstructured":"Madjarov B, Rosenfeld PJ. Serous PEDs with associated subretinal fluid unresponsive to anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2009;50:238.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ophtha.2010.04.017","volume":"118","author":"BL Sikorski","year":"2011","unstructured":"Sikorski BL, Bukowska D, Kaluzny JJ, Szkulmowski M, Kowalczyk A, Wojtkowski M. Drusen with accompanying fluid underneath the sensory retina. Ophthalmology. 2011;118:82\u201392. https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.017.","journal-title":"Ophthalmology"},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242:123\u201362. https:\/\/doi.org\/10.1159\/000502041.","journal-title":"Ophthalmologica"},{"key":"1093_CR38","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP, et al. Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina. 2021;41:1579\u201386. https:\/\/doi.org\/10.1097\/IAE.0000000000003194.","journal-title":"Retina"},{"key":"1093_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/eye.2016.208","volume":"31","author":"M Gemenetzi","year":"2017","unstructured":"Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye (Lond). 2017;31:1\u20139. https:\/\/doi.org\/10.1038\/eye.2016.208.","journal-title":"Eye (Lond)"},{"key":"1093_CR40","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","volume":"36","author":"KL Spooner","year":"2022","unstructured":"Spooner KL, Fraser-Bell S, Hong TH, Wong JG, Chang AA. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye (Lond). 2022;36:1194\u2013201. https:\/\/doi.org\/10.1038\/s41433-021-01620-z.","journal-title":"Eye (Lond)"},{"key":"1093_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.mod.2019.103579","volume":"160","author":"D Ribatti","year":"2019","unstructured":"Ribatti D. The discovery of the fundamental role of VEGF in the development of the vascular system. Mech Dev. 2019;160: 103579. https:\/\/doi.org\/10.1016\/j.mod.2019.103579.","journal-title":"Mech Dev"},{"key":"1093_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.943915","volume":"10","author":"D Song","year":"2022","unstructured":"Song D, Liu P, Shang K, Ma Y. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front Bioeng Biotechnol. 2022;10: 943915. https:\/\/doi.org\/10.3389\/fbioe.2022.943915.","journal-title":"Front Bioeng Biotechnol"},{"key":"1093_CR43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125:878\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.026.","journal-title":"Ophthalmology"},{"key":"1093_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamaophthalmol.2022.1357","volume":"140","author":"NS Patil","year":"2022","unstructured":"Patil NS, Mihalache A, Dhoot AS, Popovic MM, Muni RH, Kertes PJ. Association between visual acuity and residual retinal fluid following intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis. JAMA Ophthalmol. 2022;140:611\u201322. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.1357.","journal-title":"JAMA Ophthalmol"},{"key":"1093_CR45","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.2147\/opth.S279845","volume":"14","author":"SD Adrean","year":"2020","unstructured":"Adrean SD, Chaili S, Pirouz A, Grant S. Central serous chorioretinopathy in elderly patients mimicking occult neovascular age-related macular degeneration. Clin Ophthalmol. 2020;14:4073\u20138. https:\/\/doi.org\/10.2147\/opth.S279845.","journal-title":"Clin Ophthalmol"},{"key":"1093_CR46","unstructured":"Cheong E. Is it AMD or vitelliform? 2023. Accessed 15 Nov 2023, https:\/\/www.optometrytimes.com\/view\/is-it-amd-or-vitelliform-"},{"key":"1093_CR47","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ophtha.2014.06.013","volume":"121","author":"JY Lee","year":"2014","unstructured":"Lee JY, Folgar FA, Maguire MG, et al. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014;121:2423\u201331. https:\/\/doi.org\/10.1016\/j.ophtha.2014.06.013.","journal-title":"Ophthalmology"},{"key":"1093_CR48","doi-asserted-by":"publisher","first-page":"9994098","DOI":"10.1155\/2021\/9994098","volume":"2021","author":"C Metrangolo","year":"2021","unstructured":"Metrangolo C, Donati S, Mazzola M, et al. OCT biomarkers in neovascular age-related macular degeneration: a narrative review. J Ophthalmol. 2021;2021:9994098. https:\/\/doi.org\/10.1155\/2021\/9994098.","journal-title":"J Ophthalmol"},{"key":"1093_CR49","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.5301\/oapoc.0000009","volume":"1","author":"H Querques","year":"2017","unstructured":"Querques H, Pastore MR, Khlifi H, Georges A, Querques L, Souied EH. Integrated imaging of avascular serous pigment epithelium detachment in age-related macular degeneration. Opthalmol Point Care. 2017;1:e36-44. https:\/\/doi.org\/10.5301\/oapoc.0000009.","journal-title":"Opthalmol Point Care"},{"key":"1093_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4.","journal-title":"Eye (Lond)"},{"key":"1093_CR51","first-page":"111","volume":"3","author":"R Gallego-Pinazo","year":"2014","unstructured":"Gallego-Pinazo R, Dolz-Marco R, G\u00f3mez-Ulla F, Mrejen S, Freund KB. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014;3:111\u20135.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"1093_CR52","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1097\/iae.0000000000002662","volume":"40","author":"H Hwang","year":"2020","unstructured":"Hwang H, Kim JY, Kim KT, Chae JB, Kim DY. Flat irregular pigment epithelium detachment in central serous chorioretinopathy: a form of pachychoroid neovasculopathy? Retina. 2020;40:1724\u201333. https:\/\/doi.org\/10.1097\/iae.0000000000002662.","journal-title":"Retina"},{"key":"1093_CR53","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ajo.2015.02.002","volume":"159","author":"R Hage","year":"2015","unstructured":"Hage R, Mrejen S, Krivosic V, Quentel G, Tadayoni R, Gaudric A. Flat irregular retinal pigment epithelium detachments in chronic central serous chorioretinopathy and choroidal neovascularization. Am J Ophthalmol. 2015;159:890\u2013903.e3. https:\/\/doi.org\/10.1016\/j.ajo.2015.02.002.","journal-title":"Am J Ophthalmol"},{"key":"1093_CR54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/iae.0000000000001580","volume":"38","author":"E Bousquet","year":"2018","unstructured":"Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A. Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina. 2018;38:629\u201338. https:\/\/doi.org\/10.1097\/iae.0000000000001580.","journal-title":"Retina"},{"key":"1093_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40662-023-00349-y","volume":"10","author":"X Zhang","year":"2023","unstructured":"Zhang X, Lim CZF, Chhablani J, Wong YM. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond). 2023;10:33. https:\/\/doi.org\/10.1186\/s40662-023-00349-y.","journal-title":"Eye Vis (Lond)"},{"key":"1093_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100972","volume":"86","author":"U Schmidt-Erfurth","year":"2022","unstructured":"Schmidt-Erfurth U, Reiter GS, Riedl S, et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Prog Retin Eye Res. 2022;86: 100972. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100972.","journal-title":"Prog Retin Eye Res"},{"key":"1093_CR57","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Chakravarthy U, Loewenstein A, Chew EY, Schmidt-Erfurth U. Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration. Am J Ophthalmol. 2021;224:267\u201381. https:\/\/doi.org\/10.1016\/j.ajo.2020.12.012.","journal-title":"Am J Ophthalmol"},{"key":"1093_CR58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","volume":"128","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Clemons TE, Domalpally A, et al. Retinal specialist versus artificial intelligence detection of retinal fluid from OCT: Age-Related Eye Disease Study 2: 10-year follow-on study. Ophthalmology. 2021;128:100\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.038.","journal-title":"Ophthalmology"},{"key":"1093_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"42","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW. Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina. 2022;42:589\u2013606. https:\/\/doi.org\/10.1097\/IAE.0000000000003283.","journal-title":"Retina"},{"key":"1093_CR60","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00006982-200512000-00016","volume":"25","author":"D Pauleikhoff","year":"2005","unstructured":"Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina. 2005;25:1065\u201384. https:\/\/doi.org\/10.1097\/00006982-200512000-00016.","journal-title":"Retina"},{"key":"1093_CR61","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046.","journal-title":"Ophthalmology"},{"key":"1093_CR62","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123:60\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.013.","journal-title":"Ophthalmology"},{"key":"1093_CR63","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.017.","journal-title":"Ophthalmology"},{"key":"1093_CR64","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.037.","journal-title":"Ophthalmology"},{"key":"1093_CR65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","volume":"126","author":"C Bailey","year":"2019","unstructured":"Bailey C, Scott LJ, Rogers CA, et al. Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial. Ophthalmology. 2019;126:75\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2018.07.013.","journal-title":"Ophthalmology"},{"key":"1093_CR66","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150\u201361. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.015.","journal-title":"Ophthalmology"},{"key":"1093_CR67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamaophthalmol.2020.0437","volume":"138","author":"E Daniel","year":"2020","unstructured":"Daniel E, Maguire MG, Grunwald JE, et al. Incidence and progression of nongeographic atrophy in the comparison of age-related macular degeneration treatments trials (CATT) clinical trial. JAMA Ophthalmol. 2020;138:510\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0437.","journal-title":"JAMA Ophthalmol"},{"key":"1093_CR68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/aos.15309","volume":"101","author":"J S\u00e1nchez-Monroy","year":"2023","unstructured":"S\u00e1nchez-Monroy J, Nguyen V, Puzo M, et al. Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5 years of follow-up from Fight Retinal Blindness registry. Acta Ophthalmol. 2023;101:457\u201364. https:\/\/doi.org\/10.1111\/aos.15309.","journal-title":"Acta Ophthalmol"},{"key":"1093_CR69","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1111\/aos.14905","volume":"100","author":"S Llorente-Gonz\u00e1lez","year":"2022","unstructured":"Llorente-Gonz\u00e1lez S, Hernandez M, Gonz\u00e1lez-Zamora J, et al. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world. Acta Ophthalmol. 2022;100:e521\u201331. https:\/\/doi.org\/10.1111\/aos.14905.","journal-title":"Acta Ophthalmol"},{"key":"1093_CR70","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/bjophthalmol-2020-318688","volume":"106","author":"MA Zarbin","year":"2022","unstructured":"Zarbin MA, Hill L, Maunz A, Gliem M, Stoilov I. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. Br J Ophthalmol. 2022;106:1561\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318688.","journal-title":"Br J Ophthalmol"},{"key":"1093_CR71","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126:723\u201334. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025.","journal-title":"Ophthalmology"},{"key":"1093_CR72","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237\u201345. https:\/\/doi.org\/10.1016\/j.ophtha.2013.12.029.","journal-title":"Ophthalmology"},{"key":"1093_CR73","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.oret.2024.05.019","volume":"8","author":"A Arrigo","year":"2024","unstructured":"Arrigo A, Aragona E, Battaglia Parodi M, Bandello F. Quantitative multimodal imaging characterization of intraretinal cysts versus degenerative pseudocysts in neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8:1118\u201326. https:\/\/doi.org\/10.1016\/j.oret.2024.05.019.","journal-title":"Ophthalmol Retina."},{"key":"1093_CR74","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s40123-023-00727-8","volume":"12","author":"M Menean","year":"2023","unstructured":"Menean M, Sacconi R, Vujosevic S, et al. Subretinal pseudocysts: a comprehensive analysis of this novel OCT finding. Ophthalmol Ther. 2023;12:2035\u201348. https:\/\/doi.org\/10.1007\/s40123-023-00727-8.","journal-title":"Ophthalmol Ther"},{"key":"1093_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40942-022-00379-z","volume":"8","author":"R Hayashi-Mercado","year":"2022","unstructured":"Hayashi-Mercado R, P\u00e9rez-Monta\u00f1o C, Reyes-S\u00e1nchez J, Ram\u00edrez-Estudillo A. Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab. Int J Retina Vitreous. 2022;8:29. https:\/\/doi.org\/10.1186\/s40942-022-00379-z.","journal-title":"Int J Retina Vitreous"},{"key":"1093_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajo.2010.02.019","volume":"150","author":"SY Cohen","year":"2010","unstructured":"Cohen SY, Dubois L, Nghiem-Buffet S, et al. Retinal pseudocysts in age-related geographic atrophy. Am J Ophthalmol. 2010;150:211-7.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.02.019.","journal-title":"Am J Ophthalmol"},{"key":"1093_CR77","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1167\/iovs.09-5114","volume":"51","author":"M-H Nghiem-Buffet","year":"2010","unstructured":"Nghiem-Buffet M-H, Cohen SY, Dubois L, et al. Pseudo-cysts: a previously undescribed sign of geographic atrophy. Invest Ophthalmol Vis Sci. 2010;51:4932.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR78","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archophthalmol.2009.326","volume":"127","author":"SA Zweifel","year":"2009","unstructured":"Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596\u2013602. https:\/\/doi.org\/10.1001\/archophthalmol.2009.326.","journal-title":"Arch Ophthalmol"},{"key":"1093_CR79","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/iae.0000000000003127","volume":"41","author":"E Janse van Rensburg","year":"2021","unstructured":"Janse van Rensburg E, Ryu CL, Rampakakis E, Vila N, Chan EW, Chen JC. Outer retinal tubulation may result from fibrosed type 2 neovascularization: clinical observations and model of pathogenesis. Retina. 2021;41:1930\u20139. https:\/\/doi.org\/10.1097\/iae.0000000000003127.","journal-title":"Retina"},{"key":"1093_CR80","doi-asserted-by":"publisher","first-page":"14735","DOI":"10.1038\/s41598-021-94310-5","volume":"11","author":"A Arrigo","year":"2021","unstructured":"Arrigo A, Aragona E, Battaglia O, et al. Outer retinal tubulation formation and clinical course of advanced age-related macular degeneration. Sci Rep. 2021;11:14735. https:\/\/doi.org\/10.1038\/s41598-021-94310-5.","journal-title":"Sci Rep"},{"key":"1093_CR81","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/life14101220","volume":"14","author":"AD Moraru","year":"2024","unstructured":"Moraru AD, Danielescu C, Iorga RE, Moraru RL, Zemba M, Branisteanu DC. Review of guideline recommendations for optimal anti-VEGF therapy in age-related macular degeneration. Life (Basel). 2024;14:1220. https:\/\/doi.org\/10.3390\/life14101220.","journal-title":"Life (Basel)"},{"key":"1093_CR82","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying GS, Toth CA, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2019;126:252\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.035.","journal-title":"Ophthalmology"},{"key":"1093_CR83","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:865\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.002.","journal-title":"Ophthalmology"},{"key":"1093_CR84","first-page":"97","volume":"62","author":"A Iyer","year":"2021","unstructured":"Iyer A, Muste J, Kalur A, Singh RP. Relationship between intraretinal and subretinal fluid with visual acuity in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2021;62:97.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR85","first-page":"917","volume":"64","author":"G Weigert","year":"2023","unstructured":"Weigert G, Deak GG, Michl M, et al. Development of fibrosis and atrophy in nAMD in regard to fluid volume (IRF, SRF, PED) and fluctuation localization (1, 3, 6\u00a0mm). Invest Ophthalmol Vis Sci. 2023;64:917.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR86","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/aos.13989","volume":"97","author":"S Aurell","year":"2019","unstructured":"Aurell S, Sjovall K, Paul A, Moren A, Granstam E. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration. Acta Ophthalmol. 2019;97:519\u201324. https:\/\/doi.org\/10.1111\/aos.13989.","journal-title":"Acta Ophthalmol"},{"key":"1093_CR87","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1167\/iovs.15-18494","volume":"57","author":"P Roberts","year":"2016","unstructured":"Roberts P, Baumann B, Lammer J, et al. Retinal pigment epithelial features in central serous chorioretinopathy identified by polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci. 2016;57:1595\u2013603. https:\/\/doi.org\/10.1167\/iovs.15-18494.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR88","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40123-020-00291-5","volume":"9","author":"M Karampelas","year":"2020","unstructured":"Karampelas M, Malamos P, Petrou P, Georgalas I, Papaconstantinou D, Brouzas D. Retinal pigment epithelial detachment in age-related macular degeneration. Ophthalmol Ther. 2020;9:739\u201356. https:\/\/doi.org\/10.1007\/s40123-020-00291-5.","journal-title":"Ophthalmol Ther"},{"key":"1093_CR89","doi-asserted-by":"publisher","first-page":"AMD160","DOI":"10.1167\/iovs.18-24882","volume":"59","author":"CA Curcio","year":"2018","unstructured":"Curcio CA. Soft drusen in age-related macular degeneration: Biology and targeting via the oil spill strategies. Invest Ophthalmol Vis Sci. 2018;59:AMD160\u201381. https:\/\/doi.org\/10.1167\/iovs.18-24882.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR90","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017178","volume":"5","author":"Y Yonekawa","year":"2014","unstructured":"Yonekawa Y, Kim IK. Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med. 2014;5: a017178. https:\/\/doi.org\/10.1101\/cshperspect.a017178.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1093_CR91","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ophtha.2009.12.002","volume":"117","author":"C Cukras","year":"2010","unstructured":"Cukras C, Agr\u00f3n E, Klein ML, et al. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: age-related eye disease study report no. 28. Ophthalmology. 2010;117:489\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2009.12.002.","journal-title":"Ophthalmology"},{"key":"1093_CR92","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","volume":"120","author":"GS Ying","year":"2013","unstructured":"Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.042.","journal-title":"Ophthalmology"},{"key":"1093_CR93","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/iae.0000000000003083","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Rodr\u00edguez FJ, Joussen AM, et al. Management of retinal pigment epithelium tear during anti-vascular endothelial growth factor therapy. Retina. 2021;41:671\u20138. https:\/\/doi.org\/10.1097\/iae.0000000000003083.","journal-title":"Retina"},{"key":"1093_CR94","unstructured":"Sadda S, Hill L, Gune S. Presented at: 52nd Annual Scientific Meeting of The Retina Society; 11\u201315 September 2019; London, UK."},{"key":"1093_CR95","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond). 2023;37:1758\u201365. https:\/\/doi.org\/10.1038\/s41433-022-02231-y.","journal-title":"Eye (Lond)"},{"key":"1093_CR96","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/jcm4071380","volume":"4","author":"S Mrejen","year":"2015","unstructured":"Mrejen S, Jung JJ, Chen C, et al. Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med. 2015;4:1380\u2013402. https:\/\/doi.org\/10.3390\/jcm4071380.","journal-title":"J Clin Med"},{"key":"1093_CR97","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajo.2022.09.008","volume":"246","author":"KX Cheong","year":"2023","unstructured":"Cheong KX, Cheung CMG, Teo KYC. Review of fibrosis in neovascular age-related macular degeneration. Am J Ophthalmol. 2023;246:192\u2013222. https:\/\/doi.org\/10.1016\/j.ajo.2022.09.008.","journal-title":"Am J Ophthalmol"},{"key":"1093_CR98","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","volume":"6","author":"S Riedl","year":"2022","unstructured":"Riedl S, Vogl W-D, Waldstein SM, Schmidt-Erfurth U, Bogunovi\u0107 H. Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol Retina. 2022;6:291\u20137. https:\/\/doi.org\/10.1016\/j.oret.2021.12.007.","journal-title":"Ophthalmol Retina"},{"key":"1093_CR99","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000536278","volume":"247","author":"CR Clemens","year":"2024","unstructured":"Clemens CR, Eter N, Alten F. Current perspectives on type 3 macular neovascularization due to age-related macular degeneration. Ophthalmologica. 2024;247:73\u201384. https:\/\/doi.org\/10.1159\/000536278.","journal-title":"Ophthalmologica"},{"key":"1093_CR100","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40123-020-00327-w","volume":"10","author":"TM Aslam","year":"2021","unstructured":"Aslam TM, Mahmood S, Balaskas K, Hoyle DC. Statistical modelling of the visual impact of subretinal fluid and associated features. Ophthalmol Ther. 2021;10:127\u201335. https:\/\/doi.org\/10.1007\/s40123-020-00327-w.","journal-title":"Ophthalmol Ther"},{"key":"1093_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000353","volume":"4","author":"E Jelin","year":"2019","unstructured":"Jelin E, Wisloff T, Jorstad OK, Heiberg T, Moe MC. Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmol. 2019;4: e000353. https:\/\/doi.org\/10.1136\/bmjophth-2019-000353.","journal-title":"BMJ Open Ophthalmol"},{"key":"1093_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1: 100076. https:\/\/doi.org\/10.1016\/j.xops.2021.100076.","journal-title":"Ophthalmol Sci"},{"key":"1093_CR103","first-page":"461","volume":"64","author":"MS Spitzer","year":"2023","unstructured":"Spitzer MS. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the phase 3 PULSAR trial. Invest Ophthalmol Vis Sci. 2023;64:461.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR104","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"R Mori","year":"2023","unstructured":"Mori R, Honda S, Gomi F, et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol. 2023;67:301\u201310. https:\/\/doi.org\/10.1007\/s10384-023-00985-w.","journal-title":"Jpn J Ophthalmol"},{"key":"1093_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-325640","author":"D Zur","year":"2024","unstructured":"Zur D, Guymer R, Korobelnik JF, et al. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration. Br J Ophthalmol. 2024. https:\/\/doi.org\/10.1136\/bjo-2024-325640.","journal-title":"Br J Ophthalmol"},{"key":"1093_CR106","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(13)61501-9.","journal-title":"Lancet"},{"key":"1093_CR107","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2013a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31. https:\/\/doi.org\/10.1186\/s12886-016-0207-3.","journal-title":"BMC Ophthalmol"},{"key":"1093_CR108","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2017.10.015","volume":"185","author":"TM Aslam","year":"2018","unstructured":"Aslam TM, Zaki HR, Mahmood S, et al. Use of a neural net to model the impact of optical coherence tomography abnormalities on vision in age-related macular degeneration. Am J Ophthalmol. 2018;185:94\u2013100. https:\/\/doi.org\/10.1016\/j.ajo.2017.10.015.","journal-title":"Am J Ophthalmol"},{"key":"1093_CR109","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/iovs.63.6.17","volume":"63","author":"JP Ehlers","year":"2022","unstructured":"Ehlers JP, Patel N, Kaiser PK, et al. The association of fluid volatility with subretinal hyperreflective material and ellipsoid zone integrity in neovascular AMD. Invest Ophthalmol Vis Sci. 2022;63:17. https:\/\/doi.org\/10.1167\/iovs.63.6.17.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1093_CR110","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/eye.2016.18","volume":"30","author":"JM Baxter","year":"2016","unstructured":"Baxter JM, Fotheringham AJ, Foss AJ. Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (Lond). 2016;30:698\u2013704. https:\/\/doi.org\/10.1038\/eye.2016.18.","journal-title":"Eye (Lond)"},{"key":"1093_CR111","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.2147\/OPTH.S273564","volume":"14","author":"D Bhagat","year":"2020","unstructured":"Bhagat D, Kirby B, Bhatt H, Jager R, George M, Sheth V. Patient preferences associated with anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2020;14:2975\u201382. https:\/\/doi.org\/10.2147\/OPTH.S273564.","journal-title":"Clin Ophthalmol"},{"key":"1093_CR112","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1007\/s12325-022-02248-5","volume":"39","author":"A Skelly","year":"2022","unstructured":"Skelly A, Taylor N, Fasser C, Malkowski JP, Goswami P, Downey L. Patient preferences in the management of wet age-related macular degeneration: a conjoint analysis. Adv Ther. 2022;39:4808\u201320. https:\/\/doi.org\/10.1007\/s12325-022-02248-5.","journal-title":"Adv Ther"},{"key":"1093_CR113","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053.","journal-title":"Ophthalmology"},{"key":"1093_CR114","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1038\/s41598-023-32417-7","volume":"13","author":"CJ Huang","year":"2023","unstructured":"Huang CJ, Hsia Y, Wang SW, et al. Characteristics and response of subretinal hyperreflective material to anti-vascular endothelial growth factor in myopic choroidal neovascularization. Sci Rep. 2023;13:5431. https:\/\/doi.org\/10.1038\/s41598-023-32417-7.","journal-title":"Sci Rep"},{"key":"1093_CR115","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ebiom.2018.11.029","volume":"38","author":"K Little","year":"2018","unstructured":"Little K, Ma JH, Yang N, Chen M, Xu H. Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283\u201391. https:\/\/doi.org\/10.1016\/j.ebiom.2018.11.029.","journal-title":"EBioMedicine"},{"key":"1093_CR116","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12886-018-0960-6","volume":"18","author":"A Kovacs","year":"2018","unstructured":"Kovacs A, Kiss T, Rarosi F, Somfai GM, Facsko A, Degi R. The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration. BMC Ophthalmol. 2018;18:298. https:\/\/doi.org\/10.1186\/s12886-018-0960-6.","journal-title":"BMC Ophthalmol"},{"key":"1093_CR117","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.0905010106","volume":"106","author":"M Saint-Geniez","year":"2009","unstructured":"Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D\u2019Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA. 2009;106:18751\u20136. https:\/\/doi.org\/10.1073\/pnas.0905010106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1093_CR118","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012;122:4213\u20137. https:\/\/doi.org\/10.1172\/JCI65157.","journal-title":"J Clin Invest"},{"key":"1093_CR119","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.ajpath.2019.04.005","volume":"189","author":"EH Sohn","year":"2019","unstructured":"Sohn EH, Flamme-Wiese MJ, Whitmore SS, et al. Choriocapillaris degeneration in geographic atrophy. Am J Pathol. 2019;189:1473\u201380. https:\/\/doi.org\/10.1016\/j.ajpath.2019.04.005.","journal-title":"Am J Pathol"},{"key":"1093_CR120","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/jad-2010-100219","volume":"21","author":"WR Brown","year":"2010","unstructured":"Brown WR. A review of string vessels or collapsed, empty basement membrane tubes. J Alzheimers Dis. 2010;21:725\u201339. https:\/\/doi.org\/10.3233\/jad-2010-100219.","journal-title":"J Alzheimers Dis"},{"key":"1093_CR121","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.mvr.2010.02.011","volume":"79","author":"S Li Calzi","year":"2010","unstructured":"Li Calzi S, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, Grant MB. EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res. 2010;79:207\u201316. https:\/\/doi.org\/10.1016\/j.mvr.2010.02.011.","journal-title":"Microvasc Res"},{"key":"1093_CR122","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunovi\u0107 H. Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration. Ophthalmology. 2020;127:1211\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.010.","journal-title":"Ophthalmology"},{"key":"1093_CR123","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00417-020-05021-y","volume":"259","author":"T Bacci","year":"2021","unstructured":"Bacci T, Essilfie JO, Leong BCS, Freund KB. Exudative non-neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2021;259:1123\u201334. https:\/\/doi.org\/10.1007\/s00417-020-05021-y.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1093_CR124","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1111\/j.1755-3768.2011.02144.x","volume":"89","author":"B Wolff","year":"2011","unstructured":"Wolff B, Maftouhi MQ, Mateo-Montoya A, Sahel JA, Mauget-Fa\u00ffsse M. Outer retinal cysts in age-related macular degeneration. Acta Ophthalmol. 2011;89:e496\u20139. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02144.x.","journal-title":"Acta Ophthalmol"},{"key":"1093_CR125","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/jop.2021.0103","volume":"38","author":"JH Kim","year":"2022","unstructured":"Kim JH, Kim JW, Kim CG. Difference between the incidence of retinal fluid subtypes and their association with visual outcomes according to the types of macular neovascularization in a Korean population. J Ocul Pharmacol Ther. 2022;38:261\u20138. https:\/\/doi.org\/10.1089\/jop.2021.0103.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1093_CR126","doi-asserted-by":"publisher","first-page":"23643","DOI":"10.1038\/s41598-021-03053-w","volume":"11","author":"W Yoon","year":"2021","unstructured":"Yoon W, Yoon J, Na SK, et al. Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization. Sci Rep. 2021;11:23643. https:\/\/doi.org\/10.1038\/s41598-021-03053-w.","journal-title":"Sci Rep"},{"key":"1093_CR127","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41598-022-07108-4","volume":"12","author":"HJ Cho","year":"2022","unstructured":"Cho HJ, Song MY, Yoon W, et al. Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment. Sci Rep. 2022;12:3167. https:\/\/doi.org\/10.1038\/s41598-022-07108-4.","journal-title":"Sci Rep"},{"key":"1093_CR128","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/iae.0000000000003261","volume":"42","author":"A Sharma","year":"2022","unstructured":"Sharma A, Cheung CMG, Arias-Barquet L, et al. Fluid-based visual prognostication in type 3 macular neovascularization-FLIP-3 study. Retina. 2022;42:107\u201313. https:\/\/doi.org\/10.1097\/iae.0000000000003261.","journal-title":"Retina"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01093-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T14:54:15Z","timestamp":1739458455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01093-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Alexander JE Foss has received writing support from Boehringer Ingelheim. David Almeida is Co-Founder and Chief Medical Advisor of Citrus Therapeutics and holds equity with this company. David Almeida declares involvement with AbbVie, ACELYRIN, Alcon, Alimera Sciences, Allergan, Bausch\u2009+\u2009Lomb, Bayer, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, Novartis, Opthea, Regeneron, REGENXBIO, Roche, Samsara Vision and Spherix Consulting Group. Chui Ming Gemmy Cheung declares involvement with Bayer, Boehringer Ingelheim, Iveric Bio, Novartis, Roche, Topcon, and Zeiss. Yuichiro Ogura declares consultancy for Alcon Japan, Apellis, Bayer, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd, HOYA, Iveric Bio, Kyoto Drug Discovery & Development, Novartis, Senju; research support from Bayer, Kowa, Nikon Healthcare, Novartis, Santen, Topcon, and ZEISS; and is an employee of Genentech, Inc. Eduard de Cock and Theo Empeslidis are employees of Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}